Claims for Patent: 10,064,920

✉ Email this page to a colleague

Summary for Patent: 10,064,920

Title:	Method for controlled ovarian stimulation using FSH and hCG
Abstract:	A product comprising follicle stimulating hormone (FSH) and human chorionic gonadotropin (hCG) for the treatment of infertility.
Inventor(s):	Saez; Joan-Carles Arce (Dragor, DK)
Assignee:	Ferring B.V. (Hoofddorp, NL)
Application Number:	15/090,419
Patent Claims:	1. A method of developing a top quality embryo comprising a step of administering to a subject starting on day one and continuing for two to twenty days: a dose of, or equivalent to, 75 to 250 IU follicle stimulating hormone (FSH) per day; and a dose of, or equivalent to, 140 to 190 IU human chorionic gonadotropin (hCG) per day; and producing at least one top-quality embryo from and oocyte retrieved form the subject; wherein the at least one top quality embryo has four to five cells on day 2 after oocyte retrieval, seven or more cells on day 3 after oocyte retrieval, equally sized blastomeres and 20% fragmentation on day 3 after oocyte retrieval and no multinucleation. 2. A method according to claim 1, wherein the FSH is administered at a dose equivalent to, 100 and 200 IU FSH per day. 3. A method according to claim 2, wherein the hCG is administered at a dose equivalent to, 140 to 160 IU hCG per day. 4. A method according to claim 2, wherein the hCG is administered at a dose of, or a dose equivalent to, about 150 IU hCG per day. 5. A method according to claim 1, wherein the FSH is adiminstered at a dose equivalent to, about 150 IU FSH per day. 6. A method according to claim 5, wherein the hCG is administered at a dose of, or a dose equivalent to, about 150 IU hCG per day. 7. A method according to claim 1, wherein the hCG is administered at a dose equivalent to, 140 to 160 IU hCG per day. 8. A method according to claim 1, wherein the hCG is administered at a dose of, or a dose equivalent to, about 150 IU hCG per day. 9. A method according to claim 1, wherein the administering continues for seven to twenty days. 10. A method according to claim 1, wherein the administering continues for nine to thirteen days. 11. A method according to claim 1, wherein the administering continues for ten to eleven days. 12. A method according to claim 1, wherein the FSH is recombinant FSH. 13. A method according to claim 12, wherein the hCG is recombinant hCG. 14. A method according to claim 1, wherein the hCG is recombinant hCG. 15. A method according to claim 1, comprising a further step of administration of a gnRH agonist 12 to 16 days prior to day one of the FSH/hCG treatment. 16. A method according to claim 1, further comprising freezing at least one resulting top quality embryo.

Details for Patent 10,064,920

Glossary

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974	⤷ Get Started Free	2036-04-04
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984	⤷ Get Started Free	2036-04-04
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985	⤷ Get Started Free	2036-04-04
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 16, 1990	⤷ Get Started Free	2036-04-04
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.